Lapatinib API
| Name of Product | Lapatinib API |
|---|---|
| CAS No | 231277‑92‑2 |
| Therapeutic use:- | Small‑molecule tyrosine kinase inhibitor targeting EGFR/HER2; used for HER2+ breast cancer |
| Grade | IP/USP/EP/BP |
| Form:- | API Powder |
| Status | Regular |
Product Overview
Lapatinib is a well-known oncology active pharmaceutical ingredient (API).
It is a member of a class of drugs called tyrosine kinase inhibitors.
These API work by blocking growth signals in cancer cells.
Lapatinib is used mainly in HER2 receptor-positive breast cancer.
HER2-positive cancer cells grow and multiply rapidly.
Lapatinib slows down this process by blocking two significant pathways: HER2 and EGFR.
Because of this dual action, it works where other treatments do not.
Lapatinib gives doctors another option to treat advanced breast cancer.
Lapatinib is only produced in controlled pharmaceutical factories under stringent international guidelines.
Therapeutic Applications
By targeting the cause of cancer cell growth, Lapatinib offers patients the potential to manage disease progression with fewer side effects compared to general chemotherapy.
Specification Parameters
Packaging & Storage
Each pack is nicely labeled with API name, batch no., Date of manufacture, expiry date, and handling instructions.
Lapatinib API is well packed to maintain quality and stability.